Business
Oncolytics Biotech®Partner Adlai Nortye Doses First Patient in Chinese Bridging Trial Evaluating Pelareorep-Paclitaxel Combination Treatment in Breast Cancer
Oncolytics Biotech®Partner Adlai Nortye Doses First Patient in Chinese Bridging Tria...
About this update from Oncolytics Biotech Inc.
[{"type":"text","content":"\n \n \n \n Oncolytics Biotech®Partner Adlai Nortye Doses First Patient in Chinese Bridging Trial Evaluating Pelareorep-Paclitaxel Combination Treatment in Breast Cancer\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prngen2{\nBORDER-TOP:1pt; BORDER-RIGHT:1pt; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM:1pt; PADDING-LEFT:0.50em; BORDER-LEFT:1pt; PADDING-RIGHT:0.50em\n}\n.prntblns{\nBORDER-TOP: 1pt; BORDER-RIGHT: 1pt; BORDER-COLLAPSE: collapse; BORDER-BOTTOM: 1pt; BORDER-LEFT: 1pt\n}\n \n \n \n \n \n \n PR Newswire\n \n \n \n \n \n Trial is designed to advance pelareorep's clinical development in\n \n China\n \n , the world's second-largest pharmaceutical market\n \n \n \n \n SAN DIEGO\n \n and\n \n CALGARY, AB\n \n ,\n \n Oct. 14, 2021\n \n /PRNewswire/ -- Oncolytics Biotech\n \n ®\n \n Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that its partner Adlai Nortye has initiated dosing in a bridging clinical trial evaluating the safety, tolerability, and preliminary efficacy of pelareorep-paclitaxel combination therapy in Chinese patients with advanced or metastatic breast cancer.\n \n \n \n \n \n \n \n \n \n Results from the bridging trial are expected to allow Adlai Nortye to include data from Oncolytics' North American metastatic breast cancer trials in a future submission to Chinese regulators. The first of Oncolytics' randomized phase 2 trials, IND-213, showed that treatment with pelareorep and paclitaxel led to a statistically significant increase in overall survival compared to treatment with paclitaxel alone. Oncolytics' second randomized phase 2 trial, BRACELET-1, is ongoing and evaluates pelareorep-paclitaxel combination therapy both with and without a checkpoint inhibitor.\n \n \n \"Adlai's bridging trial is an important step forward for pelareorep's clinical development path in\n \n China\n \n , which has a rapidly growing pharmaceutical market that is currently the second-largest in the world,\" said\n \n Andrew de Guttadauro\n \n , President of Oncolytics Biotech U.S. and Global Head of Business Development. \"We are very pleased that dosing in the trial has co...